ai in drug discovery

News

Mulvany hits the reset button at BenevolentAI

The shape of BenevolentAI following the return of co-founder Ken Mulvany has started to crystallise and could see the company return to private hands.

News

Ken Mulvany speaking at a BenevolentAI event in 2018

BenevolentAI CEO steps down as founders make a comeback

Jörg Möller's sojourn as chief executive of BenevolentAI has come to an abrupt end after just nine months, as the company names co-founder Ken Mulvany as its executive chairman.

News

Mirai Bio launches with plan to help genetic med developers

Flagship Pioneering's latest biotech launch, Mirai Bio, aims to help genetic medicine developers find the best way to get their drugs to patients.

News

AI firm Generate signs $1bn discovery deal with Novartis

Flagship Pioneering-backed artificial intelligence start-up Generate:Biomedicines has attracted another big pharma partnership, this time with Novartis.

News

Meet MILTON, AZ's AI that can predict 1,000+ diseases

A machine-learning tool developed by AstraZeneca and trained on UK Biobank health record data could predict over 1,000 diseases, before diagnosis, according to a paper in Nature Genetics.

Digital